Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes
Alzheimer's disease (AD) and other forms of dementia are together a leading cause of disability and death in the aging global population, imposing a high personal, societal, and economic burden. They are also among the most prominent examples of failed drug developments. Indeed, after more than 40 AD trials of anti-amyloid interventions, reduction of amyloid-β (Aβ) has never translated into clinically relevant benefits, and in several cases yielded harm. The fundamental problem is the century-old, brain-centric phenotype-based definitions of diseases that ignore causal mechanisms and comorbidities. In this hypothesis article, we discuss how such current outdated nosology of dementia is a key roadblock to precision medicine and articulate how Network Medicine enables the substitution of clinicopathologic phenotypes with molecular endotypes and propose a new framework to achieve precision and curative medicine for patients with neurodegenerative disorders.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
Journal of Alzheimer's disease : JAD - 96(2023), 1 vom: 16., Seite 47-56 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pacheco Pachado, Mayra [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.10.2023 Date Revised 21.11.2023 published: Print ClinicalTrials.gov: NCT04477785 Citation Status MEDLINE |
|---|
| doi: |
10.3233/JAD-230694 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362391289 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362391289 | ||
| 003 | DE-627 | ||
| 005 | 20231226091136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3233/JAD-230694 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362391289 | ||
| 035 | |a (NLM)37742653 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pacheco Pachado, Mayra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.10.2023 | ||
| 500 | |a Date Revised 21.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT04477785 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Alzheimer's disease (AD) and other forms of dementia are together a leading cause of disability and death in the aging global population, imposing a high personal, societal, and economic burden. They are also among the most prominent examples of failed drug developments. Indeed, after more than 40 AD trials of anti-amyloid interventions, reduction of amyloid-β (Aβ) has never translated into clinically relevant benefits, and in several cases yielded harm. The fundamental problem is the century-old, brain-centric phenotype-based definitions of diseases that ignore causal mechanisms and comorbidities. In this hypothesis article, we discuss how such current outdated nosology of dementia is a key roadblock to precision medicine and articulate how Network Medicine enables the substitution of clinicopathologic phenotypes with molecular endotypes and propose a new framework to achieve precision and curative medicine for patients with neurodegenerative disorders | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Alzheimer’s disease | |
| 650 | 4 | |a dementia | |
| 650 | 4 | |a endophenotypes | |
| 650 | 4 | |a precision medicine | |
| 650 | 4 | |a protein-protein interaction network | |
| 650 | 4 | |a systems medicine | |
| 650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
| 650 | 7 | |a Amyloid |2 NLM | |
| 700 | 1 | |a Casas, Ana I |e verfasserin |4 aut | |
| 700 | 1 | |a Elbatreek, Mahmoud H |e verfasserin |4 aut | |
| 700 | 1 | |a Nogales, Cristian |e verfasserin |4 aut | |
| 700 | 1 | |a Guney, Emre |e verfasserin |4 aut | |
| 700 | 1 | |a Espay, Alberto J |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Harald H H W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Alzheimer's disease : JAD |d 1998 |g 96(2023), 1 vom: 16., Seite 47-56 |w (DE-627)NLM097527327 |x 1875-8908 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2023 |g number:1 |g day:16 |g pages:47-56 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3233/JAD-230694 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 96 |j 2023 |e 1 |b 16 |h 47-56 | ||